Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 50 of 2529

TitleReference numberPublishedLast updated
Pulmonary artery pressure technologies for remote monitoring of chronic heart failureHTG769
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancerTA1127
Targeted-release budesonide for treating primary IgA nephropathyTA1128
Digital technologies to support self-management of COPD: early value assessmentHTG736
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapyTA1126
Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)TA1124
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)TA1125
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessmentHTG766
Digital self-help for eating disorders: early value assessmentHTG768
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)TA1123
Balloon cryoablation for Barrett's oesophagusHTG767
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122
Acoramidis for treating transthyretin amyloidosis with cardiomyopathyTA1121
Suspected cancer: recognition and referralNG12
Avelumab with axitinib for untreated advanced renal cell carcinomaTA1120
Overweight and obesity managementNG246
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)TA1118
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA1119
VA ECMO for postcardiotomy cardiogenic shock in adultsHTG762
DMD Care UK's guideline on respiratory care: NICE reviewNR2
Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiencyTA1117
Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaTA1116
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathyTA1115
Digital platforms to support cardiac rehabilitation: early value assessmentHTG761
Child maltreatment: when to suspect maltreatment in under 18sCG89
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaTA1113
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1114
Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early managementNG255
Suspected sepsis in people aged 16 or over: recognition, assessment and early managementNG253
Suspected sepsis in under 16s: recognition, diagnosis and early managementNG254
Suspected sepsis in over 16sQS213
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Intrapartum careNG235
Low-energy contact X-ray brachytherapy for rectal cancerHTG763
Fetal monitoring in labourNG229
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Delgocitinib for treating moderate to severe chronic hand eczemaTA1107
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
VA ECMO for severe acute heart failure in adultsHTG764
VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrestHTG765
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Rehabilitation for chronic neurological disorders including acquired brain injuryNG252
Head injuryQS74

Results per page

  1. 10
  2. 25
  3. 50
  4. All